Mirum Pharmaceuticals Stock Fundamentals

MIRM Stock  USD 48.30  1.58  3.38%   
Mirum Pharmaceuticals fundamentals help investors to digest information that contributes to Mirum Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Mirum Stock. The fundamental analysis module provides a way to measure Mirum Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mirum Pharmaceuticals stock.
At this time, Mirum Pharmaceuticals' Non Operating Income Net Other is very stable compared to the past year. As of the 23rd of January 2025, Income Tax Expense is likely to grow to about 936.5 K, while Operating Income is likely to drop (103.2 M).
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Mirum Pharmaceuticals Company Return On Asset Analysis

Mirum Pharmaceuticals' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Return On Asset

 = 

Net Income

Total Assets

More About Return On Asset | All Equity Analysis

Current Mirum Pharmaceuticals Return On Asset

    
  -0.091  
Most of Mirum Pharmaceuticals' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mirum Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Competition

Mirum Total Assets

Total Assets

780.79 Million

At this time, Mirum Pharmaceuticals' Total Assets are very stable compared to the past year.
Based on the latest financial disclosure, Mirum Pharmaceuticals has a Return On Asset of -0.091. This is 98.96% lower than that of the Biotechnology sector and 99.61% lower than that of the Health Care industry. The return on asset for all United States stocks is 35.0% lower than that of the firm.

Mirum Pharmaceuticals Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Mirum Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Mirum Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mirum Pharmaceuticals competition to find correlations between indicators driving Mirum Pharmaceuticals's intrinsic value. More Info.
Mirum Pharmaceuticals is rated below average in return on equity category among its peers. It is regarded second in return on asset category among its peers . At this time, Mirum Pharmaceuticals' Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Mirum Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Mirum Return On Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mirum Pharmaceuticals' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mirum Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Mirum Pharmaceuticals by comparing valuation metrics of similar companies.
Mirum Pharmaceuticals is currently under evaluation in return on asset category among its peers.

Mirum Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Mirum Pharmaceuticals from analyzing Mirum Pharmaceuticals' financial statements. These drivers represent accounts that assess Mirum Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Mirum Pharmaceuticals' important valuation drivers and their relationship over time.
202020212022202320242025 (projected)
Market Cap563.7M440.9M483.6M1.2B1.1B1.1B
Enterprise Value427.4M302.1M454.9M1.2B1.1B1.2B

Mirum Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Mirum Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Mirum Pharmaceuticals' managers, analysts, and investors.
Environmental
Governance
Social

Mirum Fundamentals

About Mirum Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Mirum Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mirum Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mirum Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-993.6 K-943.9 K
Total Revenue214.3 M225 M
Cost Of Revenue54.1 M56.8 M
Stock Based Compensation To Revenue 0.22  0.21 
Sales General And Administrative To Revenue 0.86  1.49 
Research And Ddevelopement To Revenue 0.63  0.60 
Capex To Revenue 0.11  0.12 
Revenue Per Share 4.10  4.31 
Ebit Per Revenue(0.53)(0.55)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Mirum Pharmaceuticals is a strong investment it is important to analyze Mirum Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Mirum Pharmaceuticals' future performance. For an informed investment choice regarding Mirum Stock, refer to the following important reports:
Check out Mirum Pharmaceuticals Piotroski F Score and Mirum Pharmaceuticals Altman Z Score analysis.
To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirum Pharmaceuticals. If investors know Mirum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirum Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.08)
Revenue Per Share
6.513
Quarterly Revenue Growth
0.894
Return On Assets
(0.09)
Return On Equity
(0.40)
The market value of Mirum Pharmaceuticals is measured differently than its book value, which is the value of Mirum that is recorded on the company's balance sheet. Investors also form their own opinion of Mirum Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Mirum Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirum Pharmaceuticals' market value can be influenced by many factors that don't directly affect Mirum Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mirum Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mirum Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirum Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.